Q1 Earnings Forecast for COGT Issued By HC Wainwright

Cogent Biosciences, Inc. (NASDAQ:COGT) – Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Cogent Biosciences in a research report issued on Wednesday, August 19th. HC Wainwright analyst R. Burns forecasts that the technology company will earn ($0.50) per share for the quarter. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Cogent Biosciences’ Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($1.28) EPS.

A number of other brokerages have also recently weighed in on COGT. Piper Sandler upped their price target on shares of Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday. Wedbush restated an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a research note on Friday, May 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Wednesday, July 8th. Finally, Guggenheim increased their target price on Cogent Biosciences from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.40.

Cogent Biosciences Stock Down 1.5%

Shares of COGT opened at $36.85 on Thursday. Cogent Biosciences has a fifty-two week low of $11.53 and a fifty-two week high of $43.73. The company’s fifty day moving average is $38.36 and its two-hundred day moving average is $36.63. The firm has a market cap of $6.39 billion, a PE ratio of -17.06 and a beta of 0.38. The company has a quick ratio of 13.57, a current ratio of 13.57 and a debt-to-equity ratio of 0.48.

Cogent Biosciences (NASDAQ:COGT) last issued its quarterly earnings results on Monday, August 10th. The technology company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03.

Institutional Trading of Cogent Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in COGT. Alyeska Investment Group L.P. lifted its stake in Cogent Biosciences by 9.9% in the second quarter. Alyeska Investment Group L.P. now owns 274,849 shares of the technology company’s stock valued at $10,637,000 after buying an additional 24,849 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Cogent Biosciences by 26.5% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 209,402 shares of the technology company’s stock worth $8,104,000 after acquiring an additional 43,892 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Cogent Biosciences by 21.4% in the 2nd quarter. Wellington Management Group LLP now owns 4,343,977 shares of the technology company’s stock worth $168,112,000 after acquiring an additional 765,355 shares during the period. Empowered Funds LLC acquired a new position in Cogent Biosciences during the 2nd quarter valued at about $278,000. Finally, Seven Fleet Capital Management LP bought a new position in Cogent Biosciences in the 2nd quarter worth about $5,708,637,000.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.